Stockscreener 앱 받기
1.55
1.90%
-0.03
시장 영업 전:
1.54
-0.01
-0.65%
Milestone Pharmaceuticals Inc 주식(MIST)의 최신 뉴스
Published on: 2025-07-29 04:32:28 - beatles.ru
How volatile is Milestone Pharmaceuticals Inc. stock compared to the marketGet exclusive market analysis for investors - jammulinksnews.com
Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics - Business Wire
What are analysts’ price targets for Milestone Pharmaceuticals Inc. in the next 12 monthsFree Stock Insights For Every Investor - jammulinksnews.com
How does Milestone Pharmaceuticals Inc. compare to its industry peersBuild wealth faster with high-performing stocks - jammulinksnews.com
Is it the right time to buy Milestone Pharmaceuticals Inc. stockFree Capital Allocation Plans - jammulinksnews.com
Is Milestone Pharmaceuticals Inc. stock overvalued or undervaluedSuperior returns - jammulinksnews.com
Should I hold or sell Milestone Pharmaceuticals Inc. stock in 2025Invest smarter with high-probability setups - jammulinksnews.com
What makes Milestone Pharmaceuticals Inc. stock price move sharplyMaximize profits with strategic stock selection - jammulinksnews.com
Is Milestone Pharmaceuticals Inc. stock a good hedge against inflationFree Access to Group - metal.it
Why Milestone Pharmaceuticals Inc. stock attracts strong analyst attentionFree Stock Investment Discussion Area - metal.it
Atrial Fibrillation (AF) Pipeline Market Research Report 2025 | Insights on 10+ Companies and 12+ Drugs in the Pipeline Landscape - GlobeNewswire Inc.
Is Milestone Pharmaceuticals Inc. a good long term investmentExtraordinary earning power - PrintWeekIndia
What drives Milestone Pharmaceuticals Inc. stock priceExceptional trading results - Autocar Professional
Milestone Pharmaceuticals Inc. Stock Analysis and ForecastFree Stock Movement Tracking - Autocar Professional
Is Milestone Pharmaceuticals Inc. stock a growth or value playFree Advanced Stock Screener Access - jammulinksnews.com
What analysts say about Milestone Pharmaceuticals Inc. stockConsistently superior profits - Autocar Professional
Milestone Pharmaceuticals Remains A Buying Opportunity Despite Recent Dilution (MIST) - Seeking Alpha
Piper Sandler Maintains Milestone Pharmaceuticals(MIST.US) With Buy Rating, Cuts Target Price to $4 - 富途牛牛
HC Wainwright Has Positive Estimate for MIST Q3 Earnings - Defense World
Milestone Pharmaceuticals plunges after pricing $52.5M offering - MSN
How Milestone Pharmaceuticals Inc. stock performs during market volatilityPrecision Entry Strategy - Newser
Retail investors who have a significant stake must be disappointed along with institutions after Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) market cap dropped by US$9.0m - simplywall.st
1.32%
1.06%
자본화:
|
볼륨(24시간):